MedTrace Logo

Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA

NCT07548671 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-04-23

No results posted yet for this study

Summary

This study aimed to compare the efficacy and safety of enarodustat combined with cyclosporine versus cyclosporine monotherapy in the treatment of newly-diagnosed tansfusion-dependent non-severe aplastic anemia (TD-NSAA).

Conditions

  • Transfusion-dependent Non-severe Aplastic Anemia

Interventions

DRUG

Enarodustat

Enarodustat 8mg qd

DRUG

Cyclosporine (CsA)

CsA 3-5mg/kg/d, trough concentration 100-200ng/ml

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-12-31
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07548671 on ClinicalTrials.gov